Charles River Laboratories (NYSE: CRL) reported Q4 EPS of $2.66, $0.12 better than the analyst estimate of $2.54. Revenue for the quarter came in at $1 billion versus the consensus estimate of $985.18 million.

GUIDANCE:

Charles River Laboratories sees FY2025 EPS of $9.10-$9.60, versus the consensus of $9.60.

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.